RÉSUMÉ
LIN28 is a RNA-binding protein including two highly conserved homologous, LIN28A and LIN28B. Proto-oncogenes such as LIN28A and LIN28B are generally targeted by the let-7 miRNAs in different types of human cancers. Here, we determined the expression of LIN28A in canine mammary tumor samples and the LIN28/let-7 pathway in canine mammary cell lines. In those cell lines, we identified a functional LIN28/let-7 pathway which exhibited high expression of let-7 members and low expression of its targets, including LIN28A and LIN28B. However, the mammary carcinoma tissue samples showed a frequent expression of LIN28A being expressed mainly in the epithelial cells. No association was observed between LIN28A expression and histopathological classification and grade, TNM and survival time. Our results suggested a possible role of the LIN28A protein in the development of canine mammary carcinomas due to the high frequency observed in the tumor samples (28 of 32). The in vitro experiments suggested that the LIN28/let-7 pathway is active in the tumor cells evaluated. However, more studies are necessary to elucidate the exact role of LIN28/let-7 pathway in canine mammary carcinomas.
LIN28 é uma proteína de ligação ao RNA, com duas formas homólogas altamente conservadas, LIN28A e LIN28B. Os proto-oncogenes LIN28A e LIN28B são regulados pela família de miRNAs let-7 em diferentes tipos de cânceres em humanos. No presente trabalho, o objetivo foi determinar a expressão de LIN28A em amostras de tumor mamário de cadelas e a via LIN28/let-7 em linhagens celulares mamaÌrias caninas. Nestas linhagens, atraveÌs das teÌcnicas de qPCR e RNAseq, foi identificado que a via LIN28/let-7 apresenta-se funcional, com alta expressaÌo dos membros da famiÌlia let-7 e baixa expressaÌo de seus alvos, entre eles LIN28A e LIN28B. No entanto, as amostras de tecidos de carcinomas mamaÌrios caninos demonstraram expressaÌo frequente de LIN28A, sendo observada principalmente em ceÌlulas epiteliais. NaÌo foram observadas associaçoÌes entre expressaÌo de LIN28A com classificaçaÌo e gradaçaÌo histopatoloÌgicas, TNM e tempo de sobrevida. Nossos resultados sugerem uma possível relação da proteína LIN28A no desenvolvimento de carcinomas mamários caninos devido à alta frequência observada nas amostras tumorais (28 de 32). Os experimentos in vitro sugerem que a via LIN28/let-7 é ativa nas linhagens celulares caninas avaliadas. Entretanto, estudos funcionais ainda são necessários para elucidar a função exata da via LIN28/let-7 nos carcinomas mamários caninos.
Sujet(s)
Animaux , Femelle , Chiens , Tumeurs mammaires de l'animal/génétique , Protéines de liaison à l'ARN/analyse , microARN/analyse , Réaction de polymérisation en chaîneRÉSUMÉ
Eukaryotic initiation factor 5A (eIF5A) is a conserved protein with an essential role in translation elongation. Using one and two-dimensional western blotting, we showed that the eIF5A protein level was 2-fold lower in benznidazole (BZ)-resistant (BZR and 17LER) Trypanosoma cruzi populations than in their respective susceptible counterparts (BZS and 17WTS). To confirm the role of eIF5A in BZ resistance, we transfected BZS and 17WTS with the wild-type eIF5A or mutant eIF5A-S2A (in which serine 2 was replaced by alanine). Upon overexpressing eIF5A, both susceptible lines became approximately 3- and 5-fold more sensitive to BZ. In contrast, the eIF5A-S2A mutant did not alter its susceptibility to BZ. These data suggest that BZ resistance might arise from either decreasing the translation of proteins that require eIF5A, or as a consequence of differential levels of precursors for the hypusination reactions (e.g., spermidine and trypanothione), both of which alter BZ's effects in the parasite.
Sujet(s)
Humains , Trypanocides/pharmacologie , Trypanosoma cruzi/effets des médicaments et des substances chimiques , Trypanosoma cruzi/enzymologie , Résistance aux substances/génétique , Facteurs initiation chaîne peptidique/métabolisme , Protéines de liaison à l'ARN/métabolisme , Nitroimidazoles/pharmacologie , Trypanosoma cruzi/génétique , Expression des gènes , Facteurs initiation chaîne peptidique/analyse , Facteurs initiation chaîne peptidique/effets des médicaments et des substances chimiques , Protéines de liaison à l'ARN/analyse , Protéines de liaison à l'ARN/effets des médicaments et des substances chimiquesRÉSUMÉ
An abnormality in the Lin28/let-7a axis is relevant to the progression of hepatitis B virus (HBV)-positive hepatocellular carcinoma (HCC), which could be a novel therapeutic target for this malignant tumor. The present study aimed to investigate the antiproliferative and anti-invasive effects of urolithin A in a stable full-length HBV gene integrated cell line HepG2.2.15 using CCK-8 and transwell assays. The RNA and protein expressions of targets were assessed by quantitative PCR and western blot, respectively. Results revealed that urolithin A induced cytotoxicity in HepG2.2.15 cells, which was accompanied by the cleavage of caspase-3 protein and down-regulation of Bcl-2/Bax ratio. Moreover, urolithin A suppressed the protein expressions of Sp-1, Lin28a, and Zcchc11, and elevated the expression of microRNA let-7a. Importantly, urolithin A also regulated the Lin28a/let-7a axis in transient HBx-transfected HCC HepG2 cells. Furthermore, urolithin A decelerated the HepG2.2.15 cell invasion, which was involved in suppressing the let-7a downstream factors HMGA2 and K-ras. These findings indicated that urolithin A exerted the antiproliferative effect by regulating the Lin28a/let-7a axis and may be a potential supplement for HBV-infected HCC therapy.
Sujet(s)
Humains , Protéines de liaison à l'ARN/effets des médicaments et des substances chimiques , Carcinome hépatocellulaire/traitement médicamenteux , Coumarines/pharmacologie , microARN/effets des médicaments et des substances chimiques , Tumeurs du foie/traitement médicamenteux , Valeurs de référence , Sincalide/analyse , Facteurs temps , Réplication virale/effets des médicaments et des substances chimiques , Survie cellulaire/effets des médicaments et des substances chimiques , Technique de Western , Reproductibilité des résultats , Analyse de variance , Protéines de liaison à l'ARN/analyse , Carcinome hépatocellulaire/génétique , Carcinome hépatocellulaire/virologie , microARN/analyse , Prolifération cellulaire/effets des médicaments et des substances chimiques , Cellules HepG2 , Réaction de polymérisation en chaine en temps réel , Tumeurs du foie/génétique , Tumeurs du foie/virologieRÉSUMÉ
Although active inflammation may be deleterious and indicate immunologic activation in chronically rejected grafts, the underlying mechanism of tissue destruction has been little studied. Twenty-four cases of chronic rejection (CR) with or without acute rejection (AR) were stained with antibodies against CD3, CD8, CD68, granzyme B and TIA-1, and the number of positive cells were counted. Eleven cases of AR served as controls. The number of CD3 and CD8 positive cells increased in the acute on CR group compared to the CR group. About a half of CD3 positive T cells were CD8 positive in both groups, however, the proportion of TIA-1 or granzyme B positive cells was higher in the acute on CR group. The numbers of CD3, CD68, granzyme B and TIA-1 positive cells were higher in the AR group than the acute on CR group, however, no significant difference was found between the two groups. Serum creatinine level and proteinuria at the time of biopsy and the percentages of late onset AR and graft failure rate were higher in the acute on CR group than the CR group. Summarizing, these results suggest that infiltration of activated T cells containing cytotoxic granules plays a role in graft destruction in acute on CR.